BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

551 related articles for article (PubMed ID: 26303428)

  • 1. Recent Advances in Computer-Assisted Structure-Based Identification and Design of Histone Deacetylases Inhibitors.
    Krishna S; Kumar V; Siddiqi MI
    Curr Top Med Chem; 2016; 16(9):934-47. PubMed ID: 26303428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From natural products to HDAC inhibitors: An overview of drug discovery and design strategy.
    Qiu X; Zhu L; Wang H; Tan Y; Yang Z; Yang L; Wan L
    Bioorg Med Chem; 2021 Dec; 52():116510. PubMed ID: 34826681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC inhibitor-based therapies: can we interpret the code?
    New M; Olzscha H; La Thangue NB
    Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of histone deacetylases.
    Huang Y; Shaw PG; Davidson NE
    Methods Mol Biol; 2011; 791():297-311. PubMed ID: 21913088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
    Ramaiah MJ; Tangutur AD; Manyam RR
    Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovative Strategies for Selective Inhibition of Histone Deacetylases.
    Maolanon AR; Madsen AS; Olsen CA
    Cell Chem Biol; 2016 Jul; 23(7):759-768. PubMed ID: 27447046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitors of histone deacetylase as antitumor agents: A critical review.
    Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
    Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells.
    Sundaram MK; Ansari MZ; Al Mutery A; Ashraf M; Nasab R; Rai S; Rais N; Hussain A
    Anticancer Agents Med Chem; 2018; 18(3):412-421. PubMed ID: 28925878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
    Christianson DW
    Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.
    Bassett SA; Barnett MP
    Nutrients; 2014 Oct; 6(10):4273-301. PubMed ID: 25322459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Amine-based Histone Deacetylase Inhibitors.
    Abdelkarim H; Neelarapu R; Madriaga A; Vaidya AS; Kastrati I; Karumudi B; Wang YT; Taha TY; Thatcher GRJ; Frasor J; Petukhov PA
    ChemMedChem; 2017 Dec; 12(24):2030-2043. PubMed ID: 29080240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.
    Hadnagy A; Beaulieu R; Balicki D
    Mol Cancer Ther; 2008 Apr; 7(4):740-8. PubMed ID: 18413789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discussion on structure classification and regulation function of histone deacetylase and their inhibitor.
    Han H; Feng X; He T; Wu Y; He T; Yue Z; Zhou W
    Chem Biol Drug Des; 2024 Jan; 103(1):e14366. PubMed ID: 37776270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
    Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
    Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
    Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
    Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of histone deacetylases in melanoma-a perspective from bench to bedside.
    Hornig E; Heppt MV; Graf SA; Ruzicka T; Berking C
    Exp Dermatol; 2016 Nov; 25(11):831-838. PubMed ID: 27792246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.
    Brindisi M; Cavella C; Brogi S; Nebbioso A; Senger J; Maramai S; Ciotta A; Iside C; Butini S; Lamponi S; Novellino E; Altucci L; Jung M; Campiani G; Gemma S
    Future Med Chem; 2016 Sep; 8(13):1573-87. PubMed ID: 27556815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.